[go: up one dir, main page]

UA99602C2 - Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток - Google Patents

Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток

Info

Publication number
UA99602C2
UA99602C2 UAA200906473A UAA200906473A UA99602C2 UA 99602 C2 UA99602 C2 UA 99602C2 UA A200906473 A UAA200906473 A UA A200906473A UA A200906473 A UAA200906473 A UA A200906473A UA 99602 C2 UA99602 C2 UA 99602C2
Authority
UA
Ukraine
Prior art keywords
jam
proliferation
antibody
inhibiting
tumor cells
Prior art date
Application number
UAA200906473A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ліліан Гьотш
Наталі Корва
Жан-Франсуа Хьов
Седрік Бес
Original Assignee
Пьєр Фабр Медікамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьєр Фабр Медікамент filed Critical Пьєр Фабр Медікамент
Publication of UA99602C2 publication Critical patent/UA99602C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к антителу или его функциональному фрагменту, специфически связывающемуся с JAM-A (антитела, обозначенного как 6F4), способному ингибировать пролиферацию опухолевых клеток in vitro и/или in vivo, нуклеиновой кислоты, кодирующей его, вектору, клетке-хозяину, способу получения антитела, мышиной гибридоме, продуцирующей антитело, депонированной в CNCM под номером I-3646, а также к гуманизированному антителу, полученному из исходного мышиного антитела. Изобретение также относится к композиции, содержащей данное антитело, и применению антитела для изготовления лекарства для профилактики или лечения заболевания, связанного с пролиферацией клеток.
UAA200906473A 2006-11-24 2007-11-23 Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток UA99602C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
UA99602C2 true UA99602C2 (ru) 2012-09-10

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200906473A UA99602C2 (ru) 2006-11-24 2007-11-23 Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток

Country Status (27)

Country Link
US (2) US8071730B2 (ru)
EP (1) EP2074148A1 (ru)
JP (1) JP2010509931A (ru)
KR (1) KR20090088878A (ru)
CN (1) CN101535344B (ru)
AU (1) AU2007324509B2 (ru)
BR (1) BRPI0719323A2 (ru)
CA (1) CA2670039A1 (ru)
CL (1) CL2007003357A1 (ru)
CR (1) CR10788A (ru)
CU (1) CU23792A3 (ru)
EC (1) ECSP099341A (ru)
FR (1) FR2909092B1 (ru)
GE (1) GEP20125629B (ru)
GT (1) GT200900126A (ru)
IL (1) IL198744A0 (ru)
MA (1) MA30891B1 (ru)
MX (1) MX2009005293A (ru)
NI (1) NI200900079A (ru)
NO (1) NO20092360L (ru)
NZ (1) NZ576174A (ru)
RU (1) RU2451689C2 (ru)
SA (1) SA07280637B1 (ru)
TN (1) TN2009000194A1 (ru)
TW (1) TW200829602A (ru)
UA (1) UA99602C2 (ru)
WO (1) WO2008062063A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2011053759A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
WO2012058588A2 (en) * 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
EP3489261B1 (en) 2012-08-24 2020-10-21 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
KR102812377B1 (ko) 2016-03-01 2025-05-23 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
BR112019002127A2 (pt) 2016-08-03 2019-09-17 Nextcure Inc proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
EP2363484A3 (en) * 1998-04-03 2012-04-25 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
EP2292761A1 (en) * 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
US7786266B2 (en) * 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
WO2007127476A2 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell

Also Published As

Publication number Publication date
GT200900126A (es) 2011-09-02
US20100092455A1 (en) 2010-04-15
US20120156191A1 (en) 2012-06-21
SA07280637B1 (ar) 2012-04-11
RU2009123409A (ru) 2010-12-27
CN101535344B (zh) 2013-10-16
CN101535344A (zh) 2009-09-16
US8071730B2 (en) 2011-12-06
IL198744A0 (en) 2010-02-17
KR20090088878A (ko) 2009-08-20
GEP20125629B (en) 2012-09-10
FR2909092B1 (fr) 2012-10-19
ECSP099341A (es) 2009-06-30
EP2074148A1 (en) 2009-07-01
CU23792A3 (es) 2012-03-15
CL2007003357A1 (es) 2008-04-04
NI200900079A (es) 2010-11-10
CA2670039A1 (en) 2008-05-29
AU2007324509B2 (en) 2013-01-17
TW200829602A (en) 2008-07-16
AU2007324509A1 (en) 2008-05-29
BRPI0719323A2 (pt) 2014-02-04
RU2451689C2 (ru) 2012-05-27
NZ576174A (en) 2012-03-30
FR2909092A1 (fr) 2008-05-30
NO20092360L (no) 2009-08-11
HK1132752A1 (en) 2010-03-05
JP2010509931A (ja) 2010-04-02
MX2009005293A (es) 2009-08-07
MA30891B1 (fr) 2009-11-02
TN2009000194A1 (en) 2010-10-18
WO2008062063A1 (en) 2008-05-29
CR10788A (es) 2009-06-23

Similar Documents

Publication Publication Date Title
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
UA102867C2 (ru) Антитела к cxcr4 и их применение в лечении рака
NZ754051A (en) Novel antibodies and uses thereof
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
UA95068C2 (ru) Антиген-связующая молекула, которая связывает egfr, вектор, который ее кодирует, и их применение
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
SG170080A1 (en) Human monoclonal antibodies to o8e
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
TW200740844A (en) Novel MAdCAM antibodies
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
UA107490C2 (ru) TNF-a-СВЯЗУЮЩИЙ БЕЛОК
MX369148B (es) Agentes de unión kir3dl2.
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
MY145058A (en) Prlr-specific antibody and uses thereof
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
MX2011009220A (es) Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody